Champions Oncology, Inc. - Common Stock (CSBR)
Frequently Asked Questions About Champions Oncology, Inc. - Common Stock (CSBR)
How can researchers access Champions Oncology’s services?
Researchers can access Champions Oncology's services by contacting the company directly through its official website. The team will provide information on available models, research capabilities, and how to collaborate for drug development and preclinical testing.
How does Champions Oncology contribute to cancer research?
Champions Oncology contributes to cancer research by offering advanced preclinical models that help researchers and pharmaceutical companies understand how different types of cancer respond to treatments. Their PDX models allow for more accurate simulations of human tumor behavior, which facilitates drug development and trial processes.
How does Champions Oncology support clinical trial programs?
Champions Oncology supports clinical trial programs by providing preclinical data derived from their PDX models that help predict patient responses to investigational therapies. This information can help guide trial design and inform treatment decisions in early-phase clinical studies.
Is Champions Oncology a publicly traded company?
Yes, Champions Oncology is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol CSBR. As a publicly traded entity, the company is subject to regular financial reporting and regulatory compliance.
What are the key products and services offered by Champions Oncology?
Champions Oncology offers a range of products and services, including the Champions Oncology Platform, which provides PDX models, drug response analysis, and precision oncology services. They also offer tailored experimental design and consultancy for drug developers looking to optimize their therapeutic strategies.
What distinguishes Champions Oncology from its competitors?
Champions Oncology differentiates itself through its innovative PDX models, comprehensive data analytics, and a collaborative approach with clients. Their expertise in personalized medicine and commitment to rigorous scientific standards position them as a leader in the oncology biotech sector.
What does Champions Oncology, Inc. do?
Champions Oncology, Inc. is a biotechnology company that specializes in providing solutions for personalized cancer treatment through its innovative cloud-based platform. They leverage patient-derived xenograft (PDX) models to analyze tumor responses to different therapies, enabling oncologists to make informed decisions about individualized treatment plans.
What impact does Champions Oncology aim to have on patient care?
Champions Oncology aims to positively impact patient care by contributing to the development of effective cancer therapies that are tailored to individual patients. Their work helps to enhance the precision of treatments, ultimately leading to better outcomes and improved quality of life for cancer patients.
What is a PDX model?
A PDX, or patient-derived xenograft, model is a type of preclinical model that involves transplanting a patient's tumor into immunocompromised mice. This allows researchers to study the tumor's biology and test the efficacy of various treatments in a controlled environment that closely mimics human cancer.
What is precision oncology?
Precision oncology refers to an approach in cancer treatment that utilizes information about a patient's specific tumor characteristics, including genetic mutations, to tailor therapies that are most likely to be effective. Champions Oncology plays a key role in the precision oncology landscape by providing data-driven insights for personalized treatment options.
What is the company’s growth strategy?
Champions Oncology’s growth strategy centers on expanding its product offerings, increasing market penetration in existing and new territories, and enhancing partnerships with pharmaceutical companies and research institutions. This includes investments in technology and talent to continually refine their services.
What is the mission of Champions Oncology?
The mission of Champions Oncology is to advance the field of oncology by providing cutting-edge solutions that improve cancer treatment outcomes. They strive to empower healthcare providers with the tools they need to offer personalized and effective therapies for patients facing cancer.
What recent achievements has Champions Oncology accomplished?
Recently, Champions Oncology has achieved several milestones, such as expanding its partnerships with leading pharmaceutical companies and launching new services that enhance its PDX modeling capabilities. These accomplishments reflect the company’s commitment to advancing research in oncology.
What types of cancer models does Champions Oncology offer?
Champions Oncology offers a diverse range of cancer models that include various tumor types, such as breast, lung, colorectal, and hematological cancers. Their extensive library of PDX models allows for comprehensive testing across different cancer indications.
When was Champions Oncology founded?
Champions Oncology was founded in 2009 by a team of scientists and entrepreneurs with a vision to transform cancer treatment through innovative research. Since its inception, the company has grown significantly in terms of capabilities and market reach.
Where is Champions Oncology headquartered?
Champions Oncology is headquartered in Hackensack, New Jersey. The company also has facilities and operational presence in other locations to support its research and development activities in the field of oncology.
Who are the primary clients of Champions Oncology?
The primary clients of Champions Oncology include academic research institutions, pharmaceutical companies, and biotechnology firms. These clients utilize the company's services and PDX models to accelerate their research and development workflows in cancer treatment.
What is the current price of Champions Oncology, Inc. - Common Stock?
The current price of Champions Oncology, Inc. - Common Stock is 7.310
When was Champions Oncology, Inc. - Common Stock last traded?
The last trade of Champions Oncology, Inc. - Common Stock was at 4:00 pm EDT on April 28th, 2025
What is the market capitalization of Champions Oncology, Inc. - Common Stock?
The market capitalization of Champions Oncology, Inc. - Common Stock is 98.06M
How many shares of Champions Oncology, Inc. - Common Stock are outstanding?
Champions Oncology, Inc. - Common Stock has 13.42M shares outstanding.